Sharfman WH - Search Results

1

Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.

Sznol M, Steis RG, Smith JW 2nd, Janik JE, Sharfman WH, Urba WJ, Fenton RG, Creekmore SP, Beveridge J, Longo DL. Sznol M, et al. Among authors: sharfman wh. Online J Curr Clin Trials. 1992 Jul 1;Doc No 9:[3841 words; 32 paragraphs]. Online J Curr Clin Trials. 1992. PMID: 1343617 Clinical Trial.

2

Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study.

Urba WJ, Ewel C, Kopp W, Smith JW 2nd, Steis RG, Ashwell JD, Creekmore SP, Rossio J, Sznol M, Sharfman W, et al. Urba WJ, et al. Cancer Res. 1992 May 1;52(9):2394-401. Cancer Res. 1992. PMID: 1533172 Clinical Trial.

3

The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies.

Smith JW 2nd, Urba WJ, Curti BD, Elwood LJ, Steis RG, Janik JE, Sharfman WH, Miller LL, Fenton RG, Conlon KC, et al. Smith JW 2nd, et al. Among authors: sharfman wh. J Clin Oncol. 1992 Jul;10(7):1141-52. doi: 10.1200/JCO.1992.10.7.1141. J Clin Oncol. 1992. PMID: 1607919 Clinical Trial.

4

Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.

Sznol M, Clark JW, Smith JW 2nd, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG, et al. Sznol M, et al. Among authors: sharfman wh. J Natl Cancer Inst. 1992 Jun 17;84(12):929-37. doi: 10.1093/jnci/84.12.929. J Natl Cancer Inst. 1992. PMID: 1629914

5

Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors.

Janik JE, Sznol M, Urba WJ, Figlin R, Bukowski RM, Fyfe G, Pierce WC, Belldegrun A, Sharfman WH, Smith JW 2nd, et al. Janik JE, et al. Among authors: sharfman wh. Cancer. 1993 Nov 1;72(9):2656-9. doi: 10.1002/1097-0142(19931101)72:9<2656::aid-cncr2820720922>3.0.co;2-a. Cancer. 1993. PMID: 8402486

6

Dose-related immunologic effects of levamisole in patients with cancer.

Janik J, Kopp WC, Smith JW 2nd, Longo DL, Alvord WG, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, et al. Janik J, et al. Among authors: sharfman wh. J Clin Oncol. 1993 Jan;11(1):125-35. doi: 10.1200/JCO.1993.11.1.125. J Clin Oncol. 1993. PMID: 8418223 Clinical Trial.

7

The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.

Smith JW 2nd, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, Curti BD, Creekmore SP, Holmlund JT, Fenton RG, et al. Smith JW 2nd, et al. Among authors: sharfman wh. N Engl J Med. 1993 Mar 18;328(11):756-61. doi: 10.1056/NEJM199303183281103. N Engl J Med. 1993. PMID: 8437596 Free article. Clinical Trial.

8

Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.

Gause BL, Sznol M, Kopp WC, Janik JE, Smith JW 2nd, Steis RG, Urba WJ, Sharfman W, Fenton RG, Creekmore SP, Holmlund J, Conlon KC, VanderMolen LA, Longo DL. Gause BL, et al. J Clin Oncol. 1996 Aug;14(8):2234-41. doi: 10.1200/JCO.1996.14.8.2234. J Clin Oncol. 1996. PMID: 8708712 Clinical Trial.

9

Endocrine effects of IL-1 alpha and beta administered in a phase I trial to patients with advanced cancer.

Curti BD, Urba WJ, Longo DL, Janik JE, Sharfman WH, Miller LL, Cizza G, Shimizu M, Oppenheim JJ, Alvord WG, Smith JW 2nd. Curti BD, et al. Among authors: sharfman wh. J Immunother Emphasis Tumor Immunol. 1996 Mar;19(2):142-8. doi: 10.1097/00002371-199603000-00007. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8732697 Clinical Trial.

10

Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma.

Janik JE, Miller LL, Longo DL, Powers GC, Urba WJ, Kopp WC, Gause BL, Curti BD, Fenton RG, Oppenheim JJ, Conlon KC, Holmlund JT, Sznol M, Sharfman WH, Steis RG, Creekmore SP, Alvord WG, Beauchamp AE, Smith JW 2nd. Janik JE, et al. Among authors: sharfman wh. J Natl Cancer Inst. 1996 Jan 3;88(1):44-9. doi: 10.1093/jnci/88.1.44. J Natl Cancer Inst. 1996. PMID: 8847725 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

78 results

Search Page

Filters